100 related articles for article (PubMed ID: 19785072)
1. Molecular targeting and gene delivery in bladder cancer therapy.
Voutsinas GE; Stravopodis DJ
J BUON; 2009 Sep; 14 Suppl 1():S69-78. PubMed ID: 19785072
[TBL] [Abstract][Full Text] [Related]
2. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models.
Lee CH; Wu CL; Shiau AL
J Gene Med; 2004 Dec; 6(12):1382-93. PubMed ID: 15468191
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
5. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
6. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
7. [Effects of double targeting gene therapy by suicide gene combined with endostatin gene in treatment of bladder cancer: an experimental study].
Pan JG; Zhou X; Han RF
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2700-4. PubMed ID: 19080691
[TBL] [Abstract][Full Text] [Related]
8. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
9. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
Zang Z; Mahendran R; Wu Q; Yong T; Esuvaranathan K
Int J Mol Med; 2004 Oct; 14(4):713-7. PubMed ID: 15375606
[TBL] [Abstract][Full Text] [Related]
10. Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex.
Liu X; Tian PK; Ju DW; Zhang MH; Yao M; Cao XT; Gu JR
Cancer Gene Ther; 2003 Jul; 10(7):529-39. PubMed ID: 12833133
[TBL] [Abstract][Full Text] [Related]
11. Role and rationale of gene therapy and other novel therapies in the management of NMIBC.
Lojo Rial C; Wilby D; Sooriakumaran P
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1777-82. PubMed ID: 19954289
[TBL] [Abstract][Full Text] [Related]
12. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
[TBL] [Abstract][Full Text] [Related]
14. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
Szarvas T
Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
Isayeva T; Ren C; Ponnazhagan S
Gene Ther; 2007 Jan; 14(2):138-46. PubMed ID: 16943851
[TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
Sudarshan S; Holman DH; Hyer ML; Voelkel-Johnson C; Dong JY; Norris JS
Cancer Gene Ther; 2005 Jan; 12(1):12-8. PubMed ID: 15514684
[TBL] [Abstract][Full Text] [Related]
19. Overview of targeted therapies in oncology.
Kalyn R
J Oncol Pharm Pract; 2007 Dec; 13(4):199-205. PubMed ID: 18045779
[TBL] [Abstract][Full Text] [Related]
20. Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer.
Shibata MA; Morimoto J; Ito Y; Kusakabe K; Otsuki Y
Med Electron Microsc; 2004 Dec; 37(4):216-24. PubMed ID: 15614446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
